Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity

This version was published on 1 November 2009

Ann Clin Biochem 2009;46:527-530
doi:10.1258/acb.2009.009003
© 2009 Association for Clinical Biochemistry

 

This Article

Figures Only

Full Text

Full Text (PDF)


All Versions of this Article:

acb.2009.009003v1

46/6/527

most recent


Alert me when this article is cited

Alert me if a correction is posted
Services

Email this article to a friend

Similar articles in this journal


Similar articles in PubMed

Alert me to new issues of the journal

Download to citation manager

Google Scholar

Articles by Wijnen, P A H M

Articles by Koek, G H
PubMed

PubMed Citation
Social Bookmarking

What’s this?

Case Reports


P A H M Wijnen1,*,
I Limantoro2,*,
M Drent3,
O Bekers1,
P M J C Kuijpers4 and
G H Koek2


1 Department of Clinical Chemistry;
2 Department of Internal Medicine, Division of Gastroenterology/Hepatology;
3 Department of Respiratory Medicine, ILD Care Center;
4 Department of Cardiology, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands


Corresponding author: G H Koek, Department of Internal Medicine, Division of Gastroenterology/Hepatology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands. Email: gh.koek{at}mumc.nl

Understanding the mechanisms of drug metabolism and interactions can help to prevent side-effects. Not only drug interactions, environmental factors, disease processes and ageing are factors in the inter-individual metabolic capacity variance but also genetic factors probably play an important role, as is illustrated in the case presented. Besides therapeutic drug monitoring, genotyping some important cytochrome P450 (CYP450) enzymes was of additional value in explaining why the patient developed severe adverse effects and, moreover, did not experience any therapeutical effect of venlafaxine. Results indicated that the patient was a poor metabolizer for CYP2D6, the most important phase I enzyme to metabolize venlafaxine. This corroborates that polymorphisms in the CYP450 gene influence the metabolicactivity of the corresponding enzymes, thus affecting the subsequentserum drug levels and their metabolites. This case highlightsthe potential benefit of both clinical and genetic risk stratification(pharmacogenetics) prior to treatment, either for setting theindividual dose or for making a decision about using a particulardrug.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What’s this?